Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Diluted Average) (2020 - 2025)

Apellis Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $129.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $129.9 million for Q4 2025, up 4.8% from a year ago — trailing twelve months through Dec 2025 was $129.9 million (up 4.8% YoY), and the annual figure for FY2025 was $129.9 million, up 4.8%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $129.9 million at Apellis Pharmaceuticals, up from $126.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for APLS hit a ceiling of $129.9 million in Q4 2025 and a floor of $79938.0 in Q2 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $118.3 million (2023), compared with a mean of $79.0 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 116477.59% in 2023 and later grew 2.03% in 2025.
  • Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $84.4 million in 2021, then increased by 25.7% to $106.1 million in 2022, then grew by 11.84% to $118.7 million in 2023, then rose by 4.4% to $123.9 million in 2024, then increased by 4.8% to $129.9 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $129.9 million (Q4 2025), $126.0 million (Q2 2025), and $125.5 million (Q1 2025) per Business Quant data.